Targeting Hyaluronan Signaling Overcomes Primary Effusion Lymphoma Cells Resistance to Rapamycin

Area of Science:

• Oncology
• Virology
• Immunology

Background:

• Kaposi's sarcoma-associated herpesvirus (KSHV) drives cancers in immunocompromised individuals.
• Primary effusion lymphoma (PEL) is an aggressive KSHV-associated B-cell malignancy often resistant to chemotherapy.
• Mechanisms of PEL chemoresistance are not well understood.

Purpose of the Study:

• To investigate the role of hyaluronan (HA) signaling in rapamycin resistance in PEL cells.
• To evaluate the efficacy of targeting HA signaling to overcome chemoresistance in PEL.

Main Methods:

• Demonstrated the role of HA signaling activation in rapamycin resistance in PEL cells.
• Utilized small HA oligosaccharides (oHA) to target HA signaling.
• Assessed the impact of oHA combined with rapamycin on PEL expansion in vivo.

Main Results:

• Hyaluronan (HA) signaling activation contributes to rapamycin resistance in PEL cells.
• Targeting HA signaling with oHA enhanced rapamycin efficacy against PEL.
• Combined therapy reduced PEL expansion in vivo.

Conclusions:

• HA signaling plays a critical role in PEL chemoresistance.
• Targeting HA signaling represents a promising therapeutic strategy for PEL.
• HA-targeted therapies could improve treatment outcomes and survival for PEL patients.